Taken together, our present data suggested that BRD4 inhibition by JQ1 in patients with sunitinib-sensitive and -resistant ccRCC may improve their prognosis and suppress cancer progression by comprehensively suppressing the expression of these oncogenes. The gene discussed is BRD4; the disease is nonpapillary renal cell carcinoma.